Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients
- 88 Downloads
To evaluate the efficacy of alpha-lipoic acid (ALA) administration on hormonal and metabolic parameters of obese PCOS patients.
A group of 32 obese PCOS patients were selected after informed consent. 20 patients referred to have first grade relatives with diabetes type I or II. Hormonal and metabolic parameters as well as OGTT were evaluated before and after 12 weeks of ALA integrative administration (400 mg per os every day).
ALA administration significantly decreased insulin, glucose, BMI and HOMA index. Hyperinsulinemia and insulin response to OGTT decreased both as maximal response (Δmax) and as AUC. PCOS with diabetes relatives showed the decrease also of triglyceride and GOT. Interestingly in all PCOS no changes occurred on all hormonal parameters involved in reproduction such as LH, FSH, and androstenedione.
ALA integrative administration at a low dosage as 400 mg daily improved the metabolic impairment of all PCOS patients especially in those PCOS with familiar diabetes who have a higher grade of risk of NAFLD and predisposition to diabetes.
KeywordsPCOS Hyperinsulinemia Familiar diabetes Alpha-lipoic-acid Insulin resistance
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
The study was performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards
Informed consent was obtained from all patients participating in the study.
- 2.Genazzani AD, Despini G, Santagni S, Prati S, Rattighieri E, Chierchia E, Simoncini T (2014) Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metab Synd 3:3. https://doi.org/10.4172/2161-1017.1000140 CrossRefGoogle Scholar
- 7.Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O (2004) Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 81:114–119CrossRefPubMedGoogle Scholar
- 12.Dinicola S, Chiu TTY, Unfer V, Carlomagno G, Bizzarri M (2014) The rationale of the myo-inositol and d-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol 20:1–14Google Scholar
- 15.Gomes MB, Negrato CA (2014) Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 6(1):80. doi: 10.1186/1758-5996-6-80
- 16.Scaramuzza A, Giani E, Radaelli F, Ungheri S, Macedoni M, Giudici V, Bosetti A, Ferrari M, Zuccotti GV (2015) Alpha-Lipoic acid and antioxidant diet help to improve endothelial dysfunction in adolescents with type 1 diabetes: a pilot study. J Diabetes Res. https://doi.org/10.1155/2015/474561 (Article ID 474561) Google Scholar
- 18.Madeira IR, Carvalho CN, Gazolla FM, de Matos HJ, Borges MA et al (2008) Cut-off point for Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index established from Receiver Operating Characteristic (ROC) curve in the detection of metabolic syndrome in overweight prepubertal children. Arq Bras Endocrinol Metabol 52:1466–1473CrossRefPubMedGoogle Scholar
- 27.Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW (2011) Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 34:727–729. https://doi.org/10.2337/dc10-1991 CrossRefPubMedPubMedCentralGoogle Scholar